Mirae Asset Global Investments
TRML

Mirae Asset Global Investments’s Tourmaline Bio TRML Stock Holding History

Mirae Asset Global Investments’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-993
Closed -$47.5K – 1743
2025
Q3 		$47.5K Buy
993
+1
+0.1% +$28 ﹤0.01% 1352
2025
Q2 		$15.9K Buy
992
+113
+13% +$1.83K ﹤0.01% 1428
2025
Q1 		$14.6K Buy
879
+25
+3% +$401 ﹤0.01% 1424
2024
Q4 		$17.7K Sell
854
-73
-8% -$1.84K ﹤0.01% 1437
2024
Q3 		$23.2K Buy
927
+161
+21% +$2.69K ﹤0.01% 1413
2024
Q2 		$10.1K Buy
+766
New +$12.3K ﹤0.01% 1462
2022
Q4 		– Sell
-2,967
Closed -$78K – 2604
2022
Q3 		$78K Buy
+2,967
New +$108K ﹤0.01% 2539

Mirae Asset Global Investments's TRML Position: Q4 2025 in Review

Mirae Asset Global Investments sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 993 shares — an estimated $47.5K sold.

Mirae Asset Global Investments first reported a position in TRML in Q3 2022 and held it in 7 quarters. The position peaked at $78K in Q3 2022. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

  • Mirae Asset Global Investments reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 993 Tourmaline Bio shares in Q4 2025, an estimated $47.5K.
  • Mirae Asset Global Investments first reported a position in Tourmaline Bio in Q3 2022 and held it in 7 quarters.
  • Mirae Asset Global Investments's Tourmaline Bio position peaked at $78K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Mirae Asset Global Investments's 13F filing for Q4 2025, filed 26 Jan 2026.